F A Klok1, K Schreiber2, K Stach3, W Ageno4, S Middeldorp5, S Eichinger6, A Delluc7, M Blondon8, C Ay6. 1. Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: f.a.klok@LUMC.nl. 2. Thrombosis & Thrombophilia, Guy's & St Thomas' Hospital, London SE1 7EH, United Kingdom; Department of Rheumatology, Copenhagen University Hospital at Rigshospitalet, Denmark. 3. 1st Department of Medicine, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Germany. 4. Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy. 5. Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands. 6. Department of Medicine I, Clinical Division of Haematology and Haemostaseology, Medical University Hospital, Vienna, Austria. 7. Départment de Médicine interne et de Pneumologie, Hôpital de la Cavale Blanche, Brest, France. 8. Department of Angiology and Haemostasis, Geneva University Hospital, Geneva, Switzerland.
Abstract
INTRODUCTION: The optimal management of oral contraception and menstrual bleeding during treatment of venous thromboembolism (VTE) is largely unknown. We aimed to elicit expert opinion and compare that to current practice as assessed by a world-wide international web-based survey among physicians. METHODS: 10 international thrombosis experts and 10 abnormal uterine bleeding experts independently completed a questionnaire containing three hypothetical patient cases each with four different scenarios, and additional queries covering different severities of VTE, patient circumstances, hormonal contraceptives and both thrombotic and bleeding complications. The consensus percentage was set a priori at ≥70%. The same questionnaire with randomized case scenarios was presented to international physicians via newsletters of the ISTH and national scientific communities. Differences between the expert groups and daily clinical care were assessed. RESULTS: Expert recommendations were divergent and differed in several important points from clinical practice. In contrast to common practice in which contraceptives are discontinued at the moment of a VTE diagnosis, the thrombosis experts agreed to continue oral contraception (OC) during the anticoagulation treatment period. Also, experts reached consensus on treating patients with anticoagulation-associated abnormal uterine bleeding with tranexamic acid, although this is not supported by strong evidence from the literature. No consensus was reached on the optimal anticoagulant drug class. CONCLUSIONS: International experts' opinions on handling of contraceptives and management of anticoagulant-associated abnormal uterine bleeding in female VTE patients are divergent and management in clinical practice is heterogeneous. There is a great need of further studies on these topics.
INTRODUCTION: The optimal management of oral contraception and menstrual bleeding during treatment of venous thromboembolism (VTE) is largely unknown. We aimed to elicit expert opinion and compare that to current practice as assessed by a world-wide international web-based survey among physicians. METHODS: 10 international thrombosis experts and 10 abnormal uterine bleeding experts independently completed a questionnaire containing three hypothetical patient cases each with four different scenarios, and additional queries covering different severities of VTE, patient circumstances, hormonal contraceptives and both thrombotic and bleeding complications. The consensus percentage was set a priori at ≥70%. The same questionnaire with randomized case scenarios was presented to international physicians via newsletters of the ISTH and national scientific communities. Differences between the expert groups and daily clinical care were assessed. RESULTS: Expert recommendations were divergent and differed in several important points from clinical practice. In contrast to common practice in which contraceptives are discontinued at the moment of a VTE diagnosis, the thrombosis experts agreed to continue oral contraception (OC) during the anticoagulation treatment period. Also, experts reached consensus on treating patients with anticoagulation-associated abnormal uterine bleeding with tranexamic acid, although this is not supported by strong evidence from the literature. No consensus was reached on the optimal anticoagulant drug class. CONCLUSIONS: International experts' opinions on handling of contraceptives and management of anticoagulant-associated abnormal uterine bleeding in female VTEpatients are divergent and management in clinical practice is heterogeneous. There is a great need of further studies on these topics.
Authors: Stephan V Hendriks; Frederikus A Klok; Wilhelmina J E Stenger; Albert T A Mairuhu; Jeroen Eikenboom; Jaap Fogteloo; Menno V Huisman Journal: TH Open Date: 2020-06-24
Authors: Geert-Jan Geersing; Janneke M T Hendriksen; Nicolaas P A Zuithoff; Kit C Roes; Ruud Oudega; Toshihiko Takada; Roger E G Schutgens; Karel G M Moons Journal: PLoS Med Date: 2020-06-26 Impact factor: 11.069
Authors: Ljj Scheres; Mpa Brekelmans; W Ageno; C Ay; H R Büller; S Eichinger; B A Hutten; F A Klok; S Middeldorp; K Schreiber; K Stach; M Blondon; A Delluc Journal: BJOG Date: 2018-07-20 Impact factor: 6.531
Authors: Eva N Hamulyák; Hanke M G Wiegers; Luuk J J Scheres; Barbara A Hutten; Maria E de Lange; Anne Timmermans; Peter E Westerweel; Marten R Nijziel; Marieke J H A Kruip; Marije Ten Wolde; Paula F Ypma; Frederikus A Klok; Laurens Nieuwenhuizen; Sanne van Wissen; Marcel M C Hovens; Laura M Faber; Pieter W Kamphuisen; Harry R Büller; Saskia Middeldorp Journal: Res Pract Thromb Haemost Date: 2020-12-18
Authors: Elena Campello; Luca Spiezia; Chiara Simion; Daniela Tormene; Giuseppe Camporese; Fabio Dalla Valle; Anna Poretto; Cristiana Bulato; Sabrina Gavasso; Claudia Maria Radu; Paolo Simioni Journal: J Am Heart Assoc Date: 2020-11-23 Impact factor: 5.501
Authors: Corinne LaVasseur; Suvi Neukam; Thomas Kartika; Bethany Samuelson Bannow; Joseph Shatzel; Thomas G DeLoughery Journal: Res Pract Thromb Haemost Date: 2022-08-23